Table 3.
Adjusted percent changes in survival times for viremia copy-years and cross-sectional viral load measurements among 841 cART-initiating HIV-positive MACS study participants.
| Model A* | Model B† | |||
|---|---|---|---|---|
| % Change in survival time‡ (95% CI) | AIC | % Change in survival time‡ (95% CI) | AIC | |
| Last pre-cART VL | −7 (−26, 12) | 458.1 | NA | NA |
| Most recent VL | −16 (−28, −4) | 453.8 | NA | NA |
| First post-cART VL | −14 (−27, −1) | 455.8 | NA | NA |
| Overall VCY | −18 (−39, 4) | 456.2 | −4 (−36, 27) | 458.5 |
| VCY from cART, 1y | −12 (−32, 8) | 457.5 | 11 (−44, 66) | 458.4 |
| VCY from cART, 2y | −15 (−36, 5) | 456.8 | 1 (−36, 37) | 458.6 |
| VCY from cART, 3y | −19 (−39, 1) | 455.8 | −9 (−40, 22) | 458.4 |
| VCY from cART, 4y | −20 (−40, 0) | 455.5 | −11 (−42, 19) | 458.2 |
| VCY from cART, 5y | −20 (−40, 1) | 455.7 | −9 (−40, 22) | 458.3 |
| VCY from cART, 6y | −18 (−39, 3) | 456.0 | −6 (−37, 26) | 458.5 |
| VCY from cART, 7y | −17 (−38, 5) | 456.5 | −1 (−33, 31) | 458.6 |
| VCY from cART, 8y | −17 (−38, 5) | 456.5 | −1 (−32, 31) | 458.6 |
| VCY from cART, 9y | −17 (−38, 5) | 456.6 | −1 (−32, 31) | 458.6 |
| VCY from cART, 10y | −17 (−38, 5) | 456.5 | −1 (−33, 30) | 458.6 |
| Recent VCY, 1y | −17 (−29, −5) | 453.7 | −9 (−29, 11) | 458.0 |
| Recent VCY, 2y | −20 (−32, −7) | 451.9 | −15 (−32, 2) | 456.6 |
| Recent VCY, 3y | −24 (−36, −12) | 449.1 | −21 (−37, −6) | 454.1 |
| Recent VCY, 4y | −23 (−37, −10) | 450.5 | −20 (−36, −4) | 455.0 |
| Recent VCY, 5y | −24 (−39, −10) | 450.2 | −22 (−39, −5) | 454.5 |
| Recent VCY, 6y | −26 (−41, −11) | 449.6 | −25 (−43, −6) | 453.8 |
| Recent VCY, 7y | −26 (−42, −10) | 450.5 | −24 (−43, −5) | 454.6 |
| Recent VCY, 8y | −25 (−42, −8) | 451.6 | −22 (−43, −2) | 455.4 |
| Recent VCY, 9y | −22 (−40, −5) | 453.4 | −17 (−40, 5) | 456.9 |
| Recent VCY, 10y | −22 (−41, −4) | 453.8 | −17 (−41, 6) | 457.1 |
Bold indicates statistical significance
Model A was adjusted for age (per 10-year increase), non-Caucasian race, most recent CD4+ T cell count (per 100 cells/mm3 increase with linear spline at 200 cells/mm3), baseline CD4+ T cell count (per 100 cells/mm3 increase), AIDS diagnosis prior to cART initiation, MACS study site and cohort enrollment
Model B evaluated each VCY measure jointly with the three cross-sectional VLs (last pre-cART VL, first VL after cART and the most recent VL) after adjusting for all demographic and clinical factors included in Model A. Among the three cross-sectional VLs, adjusted percent change in survival times are only shown for the most recent VL.
Percent change in survival times was estimated for each 10-fold increase in the 21 VCY measures (copy-years/mL) and 3 cross-sectional VLs (copies/mL)
Abbreviations: VCY, viremia copy-years; VL, viral load; cART, combination antiretroviral therapy; MACS, Multicenter AIDS Cohort Study; CI, confidence interval; AIC, Akaike Information Criteria